Plus Historical Balance Sheet
PSTV Stock | USD 1.34 0.03 2.29% |
Trend analysis of Plus Therapeutics balance sheet accounts such as Common Stock Shares Outstanding of 3.3 M, Liabilities And Stockholders Equity of 10.8 M, Non Current Liabilities Total of 1.9 M or Total Liab of 25.2 M provides information on Plus Therapeutics' total assets, liabilities, and equity, which is the actual value of Plus Therapeutics to its prevalent stockholders. By breaking down trends over time using Plus Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Plus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Plus Therapeutics is a good buy for the upcoming year.
Plus Therapeutics Inventory |
|
Plus |
About Plus Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Plus Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Plus Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Plus Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Plus currently owns. An asset can also be divided into two categories, current and non-current.
Plus Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Plus Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Plus Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Plus Therapeutics balance sheet. This account contains Plus Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Plus Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most accounts from Plus Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Plus Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.At this time, Plus Therapeutics' Property Plant Equipment is fairly stable compared to the past year. Capital Lease Obligations is likely to climb to about 294.6 K in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 4 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 7.0M | 5.6M | 4.2M | 4.0M | Total Assets | 22.0M | 23.9M | 11.4M | 10.8M |
Plus Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Plus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Plus Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 23.2M | 12.1M | 22.0M | 23.9M | 11.4M | 10.8M | |
Short Long Term Debt Total | 11.9M | 7.0M | 7.0M | 5.6M | 4.2M | 4.0M | |
Total Stockholder Equity | 1.2M | 3.0M | 10.8M | 6.4M | (1.3M) | (1.3M) | |
Net Debt | (5.7M) | (1.4M) | (11.4M) | (12.5M) | (4.4M) | (4.6M) | |
Cash | 17.6M | 8.3M | 18.4M | 18.1M | 8.6M | 14.2M | |
Cash And Short Term Investments | 17.6M | 8.3M | 18.4M | 18.1M | 8.6M | 14.1M | |
Common Stock Shares Outstanding | 92.3K | 295.2K | 805.9K | 1.8M | 3.1M | 3.3M | |
Liabilities And Stockholders Equity | 23.2M | 12.1M | 22.0M | 23.9M | 11.4M | 10.8M | |
Non Current Liabilities Total | 7.6M | 535K | 5.3M | 5.6M | 2.0M | 1.9M | |
Total Liab | 22.1M | 9.1M | 11.1M | 17.4M | 12.7M | 25.2M | |
Total Current Assets | 19.8M | 9.2M | 19.7M | 21.8M | 9.8M | 17.1M | |
Other Current Liab | 6K | 1.3M | 1.4M | 1.7M | 1.9M | 2.0M | |
Total Current Liabilities | 14.5M | 8.5M | 5.9M | 11.9M | 10.7M | 10.5M | |
Property Plant And Equipment Net | 3.0M | 2.5M | 1.8M | 1.6M | 1.1M | 2.0M | |
Retained Earnings | (425.3M) | (433.5M) | (446.9M) | (467.2M) | (480.5M) | (456.5M) | |
Non Current Assets Total | 3.4M | 2.9M | 2.3M | 2.1M | 1.6M | 1.5M | |
Non Currrent Assets Other | 11.7M | 72K | 16K | 12K | 32K | 30.4K | |
Net Receivables | 233K | 1.2M | 59K | 7K | 6.3K | 6.0K | |
Other Current Assets | 957K | 770K | 1.3M | 3.7M | 1.3M | 1.2M | |
Other Stockholder Equity | 426.4M | 436.5M | 457.7M | 473.6M | 479.1M | 286.3M | |
Short Term Debt | 11.2M | 6.5M | 1.8M | 1.8M | 4.1M | 4.6M | |
Common Stock | 4K | 7K | 16K | 34K | 5K | 4.8K | |
Current Deferred Revenue | 1.9M | 2.9M | 1.3M | 1.4M | 1.3M | 1.2M | |
Accounts Payable | 327K | 789K | 2.6M | 8.4M | 4.8M | 5.0M | |
Property Plant And Equipment Gross | 3.0M | 2.5M | 1.8M | 1.6M | 3.6M | 2.1M | |
Net Tangible Assets | 788K | 2.6M | 10.4M | 6.0M | 6.9M | 3.8M | |
Capital Surpluse | 413.3M | 418.4M | 426.4M | 436.5M | 502.0M | 424.5M | |
Property Plant Equipment | 2.2M | 1.8M | 1.8M | 1.6M | 1.8M | 2.0M | |
Other Assets | 72K | 652K | 16K | 12K | 10.8K | 10.3K | |
Other Liab | 6.9M | 7K | 1K | 1.6M | 1.9M | 1.4M | |
Capital Lease Obligations | 913K | 661K | 380K | 251K | 205K | 294.6K | |
Short Long Term Debt | 14.2M | 11.1M | 6.3M | 1.6M | 4.0M | 5.2M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.